Three Seasons Wealth LLC Purchases New Shares in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Key Points

• Three Seasons Wealth LLC acquired 20,324 shares of Catalyst Pharmaceuticals, valued at approximately $493,000, during the first quarter, reflecting growing institutional interest in the biopharmaceutical sector.
• Analysts have given Catalyst Pharmaceuticals a strong buy rating, with an average target price of $32.83, and a total of 79.22% of the stock owned by institutional investors.
• Insider selling has occurred recently, with Gary Ingenito selling 44,000 shares for over $1 million, representing a significant decrease in his ownership position.

Three Seasons Wealth LLC acquired a new position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 20,324 shares of the biopharmaceutical company's stock, valued at approximately $493,000.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the stock. GAMMA Investing LLC raised its holdings in Catalyst Pharmaceuticals by 26.2% during the 1st quarter. GAMMA Investing LLC now owns 2,791 shares of the biopharmaceutical company's stock worth $68,000 after purchasing an additional 579 shares during the last quarter. Summit Investment Advisors Inc. grew its position in Catalyst Pharmaceuticals by 5.2% in the 4th quarter. Summit Investment Advisors Inc. now owns 11,696 shares of the biopharmaceutical company's stock valued at $244,000 after purchasing an additional 580 shares during the period. Hohimer Wealth Management LLC grew its position in Catalyst Pharmaceuticals by 3.6% in the 1st quarter. Hohimer Wealth Management LLC now owns 18,070 shares of the biopharmaceutical company's stock valued at $438,000 after purchasing an additional 629 shares during the period. Vestcor Inc grew its position in Catalyst Pharmaceuticals by 3.0% in the 1st quarter. Vestcor Inc now owns 28,705 shares of the biopharmaceutical company's stock valued at $696,000 after purchasing an additional 840 shares during the period. Finally, Bank of Montreal Can grew its position in Catalyst Pharmaceuticals by 6.2% in the 4th quarter. Bank of Montreal Can now owns 14,879 shares of the biopharmaceutical company's stock valued at $311,000 after purchasing an additional 875 shares during the period. Institutional investors own 79.22% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on CPRX shares. Wall Street Zen downgraded shares of Catalyst Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Saturday. Cantor Fitzgerald raised shares of Catalyst Pharmaceuticals to a "strong-buy" rating in a report on Thursday, June 5th. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus target price of $32.83.

Insider Activity at Catalyst Pharmaceuticals

In other Catalyst Pharmaceuticals news, insider Preethi Sundaram sold 2,324 shares of the stock in a transaction that occurred on Tuesday, June 10th. The shares were sold at an average price of $26.41, for a total transaction of $61,376.84. Following the transaction, the insider directly owned 42,681 shares in the company, valued at $1,127,205.21. This trade represents a 5.16% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Gary Ingenito sold 200,000 shares of the stock in a transaction that occurred on Tuesday, May 13th. The shares were sold at an average price of $23.68, for a total transaction of $4,736,000.00. Following the transaction, the insider owned 68,873 shares in the company, valued at $1,630,912.64. The trade was a 74.38% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 247,924 shares of company stock worth $5,879,369. 10.40% of the stock is owned by company insiders.

Catalyst Pharmaceuticals Stock Up 1.1%

Shares of CPRX stock traded up $0.22 during trading on Friday, hitting $19.86. The company had a trading volume of 2,235,269 shares, compared to its average volume of 1,387,106. The stock's 50-day moving average is $22.26 and its two-hundred day moving average is $22.79. The stock has a market capitalization of $2.42 billion, a price-to-earnings ratio of 12.04, a price-to-earnings-growth ratio of 0.80 and a beta of 0.70. Catalyst Pharmaceuticals, Inc. has a 52 week low of $17.58 and a 52 week high of $26.58.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.